newsfilter
← Latest News
GlobeNewswire·

Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of D